• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

133.72 +0.91 (+0.69%)
Official Closing Price Updated: 7:00 PM EST, Nov 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9
...
30 31 Next >
News headline image
Merck Announces TroFuse-015 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoint of Overall Survival (OS) in Third-Line or Later Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma
November 20, 2026
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck and Isomorphic Labs Enter Strategic Research Collaboration
November 19, 2026
From Merck & Co., Inc.
Via Business Wire
News headline image
Thomas H. Glocer to Retire From Merck Board of Directors in May 2027; Douglas M. Baker, Jr. Appointed Independent Lead Director
November 18, 2026
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck Announces Update on BELLWAVE Clinical Development Program Evaluating Nemtabrutinib
November 17, 2026
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck Announces First-Quarter 2027 Dividend
November 17, 2026
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck Receives Positive EU CHMP Opinion to Expand Marketing Authorization for ENFLONSIA® (clesrovimab) to Include Children Up to 24 Months of Age Who Remain Vulnerable to Severe RSV Disease Through Their Second RSV Season
November 13, 2026
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck Receives Positive EU CHMP Opinion for WELIREG® (belzutifan) in Combination With Lenvatinib for Adults With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC) Following Treatment With an Anti-PD-1/PD-L1 Therapy
November 13, 2026
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck to Participate in the Jefferies Global Healthcare Conference in London
November 12, 2026
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck Announces Positive Results from Phase 2b Trial of Efinopegdutide in Adults with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Stage 2-3 Fibrosis
November 09, 2026
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck Initiates Phase 3 Study Evaluating Ohtuvayre® (ensifentrine) for the Prevention of COPD Exacerbations in Adult Patients Receiving Standard of Care With a History of Exacerbations
November 03, 2026
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck to Present New Data from Its Broad Oral HIV Portfolio and Pipeline at HIV Glasgow 2026
November 02, 2026
From Merck & Co., Inc.
Via Business Wire
News headline image
Lost Money on Merck & Co., Inc. Stock? Glancy Prongay Wolke & Rotter LLP Investigates Possible Securities Fraud After 1.76% Share Price Drop
October 30, 2026
From Glancy Prongay Wolke & Rotter LLP
Via Business Wire
News headline image
Did You Lose Money on Merck & Co., Inc. Stock? The Law Offices of Howard G. Smith Announces Securities Fraud Investigation After 1.76% Share Price Decline
October 30, 2026
From The Law Offices of Howard G. Smith
Via Business Wire
News headline image
Lost Money on Merck & Co., Inc. Shares? The Law Offices of Frank R. Cruz Investigates Potential Securities Fraud After 1.76% Stock Decline
October 29, 2026
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2026 Financial Results; Highlights Multiple Milestones Advancing Broad, Diverse Pipeline
October 29, 2026
From Merck & Co., Inc.
Via Business Wire
News headline image
KEYTRUDA® (pembrolizumab) as Monotherapy Reduced the Risk of Disease Progression or Death by 43% for Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy
October 26, 2026
From Merck & Co., Inc.
Via Business Wire
News headline image
Sacituzumab Tirumotecan (Sac-TMT) Reduced the Risk of Death by 32% and the Risk of Disease Progression or Death by 41% Compared to Chemotherapy in Certain Patients With Advanced or Recurrent Endometrial Cancer
October 26, 2026
From Merck & Co., Inc.
Via Business Wire
News headline image
A Personalized Cancer Therapy Delivered Positive Phase 3 Results; The Next Race Is Picking Better Targets
October 26, 2026
News Provided by Biotech Insider on behalf of MindWalk Holdings Corp. 
From Biotech Insider
Via GlobeNewswire
News headline image
Merck and Moderna Will Present Results From Landmark Phase 3 INTerpath-001 Trial for Intismeran Autogene Plus KEYTRUDA® (pembrolizumab) at ESMO 2026 Presidential Symposium
October 22, 2026
From Merck & Co., Inc.
Via Business Wire
News headline image
Brain Cancer Research: The Race for Better CNS Cancer Treatments Could Open a Multibillion-Dollar Market
October 21, 2026
Growing investment in next-generation CNS cancer therapies is driving research into targeted drugs, immunotherapy and new approaches to treating aggressive brain tumors. 
From FN Media
Via GlobeNewswire
News headline image
Brain Cancer Research: The Race for Better CNS Cancer Treatments Could Open a Multibillion-Dollar Market
October 21, 2026
EQNX::TICKER_START (NASDAQ:NTHI),(NASDAQ:NBIX),(NASDAQ:ACAD),(NASDAQ:AVXL),(NYSE:MRK) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
European Commission Approves KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer (MIBC)
October 21, 2026
From Merck & Co., Inc.
Via Business Wire
News headline image
Paul J. Diaz Elected to Merck & Co., Inc., Rahway, N.J., USA Board of Directors
October 13, 2026
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck Showcases First-Time Pivotal Phase 3 Results From Oncology Pipeline and Continued Innovative Potential of Existing Portfolio at ESMO 2026
October 13, 2026
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck Presents One-Year Results from the Pivotal Phase 2b/3 BRUNELLO Study Evaluating Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, in Adults with Diabetic Macular Edema at AAO 2026
October 10, 2026
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck to Hold Third-Quarter 2026 Sales and Earnings Conference Call Oct. 29
October 01, 2026
From Merck & Co., Inc
Via Business Wire
News headline image
Merck's Tulisokibart Met Primary and Key Secondary Endpoints in Phase 2b Study in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)
September 30, 2026
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck Enters into Exclusive Global License Agreement with SciBrunch Therapeutics for SPR2015, an Investigational Oral KRAS G12D (ON) Inhibitor
September 28, 2026
From Merck & Co., Inc.
Via Business Wire
News headline image
U.S. FDA Approves WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) for Certain Previously Treated Adult Patients With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC)
September 25, 2026
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck’s Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, Met Primary Endpoint in the Pivotal Phase 2b/3 BRUNELLO Study of Adults with Diabetic Macular Edema
September 24, 2026
From Merck & Co.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
30 31 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap